Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COASTAL: Zandelisib + Rituximab vs Standard Immunochemotherapy in Relapsed Indolent NHL
2020-004199-16Phase 3Terminated
- Sponsor
- MEI Pharma
- Start
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of zandelisib in non-Hodgkin lymphoma (NHL), follicular lymphoma (FL) and marginal zone B-cell lymphoma (MZL) (2 arms), sponsored by MEI Pharma. Primary endpoint: Progression-free survival. Started Feb 2021; status: terminated.
02
Drugs
zandelisib
03
Conditions
non-Hodgkin lymphoma (NHL)follicular lymphoma (FL)marginal zone B-cell lymphoma (MZL)
Beyond the preview
Go deeper on 2020-004199-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004199-16.